Press releases

DEINOVE immediately strengthens its cash position by €1.5 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that...

• Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences...

The current health, economic and financial crisis creates too much uncertainty to enter into a long-term full partnership around a complete...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

The equity line funding set up in December 2014 expired. It has enabled DEINOVE to raise €9.4 million net in a flexible, optimized manner...